Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma
NCT03517137Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2019
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Modified Progression-free Survival Rate at 2 years. Started Aug 2019; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03517137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517137.